Penn Medicine | Strategic Alliance Partners

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.

A preclinical study offers a foundation for a combination strategy in future clinical trials for KRAS mutations.

Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.

In pilot study, patients saved over an hour of time at every treatment visit.

Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.

Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

The Roberts Proton Therapy Center at Penn Medicine celebrated its 15th anniversary on January 24, 2025.

Dimitrios Nasioudis, MD, discusses preclinical study findings utilizing XPO1 inhibition for TP53 wild-type low-grade serous and clear cell ovarian cancer.

A national data analysis published by researchers from Penn Medicine reported that short-term mortality was not impacted for patients with advanced cancers during the shortage of generic platinum chemotherapy drugs.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.

Julia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council.

Jennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.

Jennifer R. Eads, MD, explains the relevance of negative results from the ECOG-ACRIN EA2174 trial in esophageal/gastroesophageal junction adenocarcinoma.

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.